Patents Assigned to Ambryx Biotechnology, Inc.
  • Publication number: 20100022442
    Abstract: Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrelin levels, and decreasing serum TNF-alpha levels. Compositions provided comprise a mixture of zinc-charged, fragmented proteins derived, for example, from serum or milk. Compositions are administered in a therapeutically effective amount to, for example, reduce oxidative stress levels in a mammalian subject.
    Type: Application
    Filed: July 25, 2008
    Publication date: January 28, 2010
    Applicant: Ambryx Biotechnology, Inc.
    Inventor: Men Hwei Tsai
  • Patent number: 7528108
    Abstract: Compositions and methods for treating or preventing, for example, overweight or obesity are provided. Compositions provided comprise zinc-charged, protease digested serum or milk proteins. Compositions are administered in a therapeutically effective amount to treat or prevent, for example, overweight or obesity.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: May 5, 2009
    Assignee: Ambryx Biotechnology, Inc.
    Inventor: David Men Hwei Tsai
  • Patent number: 7445784
    Abstract: This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu (SEQ ID NO: 1). The peptide induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the peptide is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. The peptide has a LD50 of 0.3-0.4 ?M, while the LD50 for zinc-charged fetuin is 3-10 ?M.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: November 4, 2008
    Assignee: Ambryx Biotechnology, Inc.
    Inventor: David Tsai
  • Patent number: 7238662
    Abstract: This invention characterizes the selective apoptotic activity of specially prepared Alpha 2-HS glycoprotein and fragments thereof. Specifically, Alpha 2-HS glycoprotein which has been overloaded with zinc, as well as fragnents thereof, selectively induce apoptosis in HT-29 (colon cancer), LNCaP (prostate cancer) and Hep G2 (hepatoma) cells while having no effect on CCD 18 Co (normal colon) cells.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: July 3, 2007
    Assignee: Ambryx Biotechnology, Inc.
    Inventor: David Tsai
  • Publication number: 20020187208
    Abstract: An extract from the Melothria Indica Lou plant, which has the effect of inhibiting the release of cytokines, including Tumor Necrosis Factor-alpha, by immune response cells, such as macrophages, for the therapeutic treatment of sepsis.
    Type: Application
    Filed: March 4, 2002
    Publication date: December 12, 2002
    Applicant: Ambryx Biotechnology, Inc.
    Inventor: David M. Tsai
  • Patent number: 6352729
    Abstract: An extract from the Melothria Indica Lou plant, which has the effect of inhibiting the release of cytokines, including Tumor Necrosis Factor-alpha, by immune response cells, such as macrophages, for the therapeutic treatment of sepsis.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: March 5, 2002
    Assignee: Ambryx Biotechnology, Inc.
    Inventor: David M Tsai
  • Patent number: 6312737
    Abstract: The invention includes a method of inducing apoptosis in cancer cells by administering an extract of Melothria indica Lou to the cancer cells. The invention also includes a method of using an extract of Melothria indica Lou to induce apoptosis in cancer cells by administering the extract to the cancer cells. The cancer cells can be leukemia cells and prostate cancer cells. Further included in the invention is a method for purifying the Melothria indica Lou into an extract used for inducing apoptosis in cancer cells.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: November 6, 2001
    Assignee: Ambryx Biotechnology, Inc.
    Inventor: David Tsai